MAPLIGHT THERAPEUTICS INC (MPLT)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, targeted treatments for central nervous system disorders.
What MAPLIGHT THERAPEUTICS INC does
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutic candidates. The company is advancing preclinical studies and clinical trials for product candidates, with an emphasis on identifying patients and expanding the scope of potential indications for its pipeline. MapLight is pursuing regulatory approvals and commercialization strategies for its therapeutic programs.
Themes: biotechnology, CNS drug development, neurology, psychiatry
Fundamentals
- Price$11.21 as of 2026-08-21 close
- Market cap$476M as of 2026-08-21
- P/En/a earnings data not available
- ROE-76.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.80 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How MPLT compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MAPLIGHT THERAPEUTICS INC looks technically
MAPLIGHT THERAPEUTICS INC (MPLT): a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 30, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 20 trading days ago. Trading volume is unusually light — only about 36% of its 30-day average.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.41 | $25.41 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with sellers in control | 48.3 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 30, in oversold territory (below 30) | 30.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($10.84 to $13.74) — its "stochastic" reading is 13 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 12.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $40.43 | $40.43 |
|---|---|---|
| From the 52-week high | it is 72.3% below its 52-week high (its highest price of the past year) | -72.3% |
| Above the 52-week low | it is 23.2% above its 52-week low (its lowest price of the past year) | +23.2% |
| Below the 52-week high | it is 72.3% below its highest point of the past year | 72.3% |
| Since a 20-day breakout | it made a new 20-day low about 20 trading days ago | 20 sessions |
| Since a 55-day breakout | it made a new 55-day low about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $40.43 (set on 2026-07-10) | $40.43 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 72.3% below its all-time high | -72.3% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $9.10 (set on 2026-07-28) | $9.10 |
| Above the all-time low | it is 23.2% above its all-time low | +23.2% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 60th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.91 between its high and its low — about 17.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.91 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.05 and $14.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.05 – $12.23 – $14.42 |
| Typical daily range (% of price) | its price moves about 17.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 17.1% |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 36% of its 30-day average | 0.36× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 17.4% since the prior reading | -17.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.14 toward sell |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 64.5% below the previous close 19 sessions ago and has not traded back through the level it left behind at 36.56 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -64.5% |
| Gap filled | a 2.5% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -7.74% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 72.4 percentage points (the stock lost 70.1% while the market gained 2.3%) | -72.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 64.8 percentage points (the stock lost 61.7% while the market gained 3.1%) | -64.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 48.4 percentage points (the stock lost 37.3% while the market gained 11.1%) | -48.4% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 3 of the 7 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 7 |
|---|---|---|
| Bearish technical signals | 3 of the 7 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 66% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 23.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -65.8% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 47% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $21.08 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -46.8% |
|---|
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Oversold (14-day RSI below 30) · MACD just crossed bullish (12/26/9) · Analyst price target recently CUT · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) · Trading below the Ichimoku cloud | Learn: adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$26.69 range $13.00 – $45.00; median $25.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MPLT
- Consensus EPS estimate-$1.09 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Timing, progress and results of preclinical studies and clinical trials are uncertain and may be materially delayed or fail to demonstrate efficacy","Ability to identify and enroll sufficient patients in trials, as well as identify suitable patient populations for product candidates, is not assured","Dependence on existing cash and investments to fund operations; additional capital raising may be necessary and may be dilutive to shareholders"]
What changed in the latest 10-Q
AI-assisted comparison of MPLT's 10-Q filed 2026-05-14 against the prior one filed 2025-12-04.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Management's Discussion and Analysis of Financial Condition and Results of Operations' changed from 19 (filed 2025-12-04) to 16 (filed 2026-05-14)
- Page number for 'Quantitative and Qualitative Disclosures About Market Risk' changed from 30 (filed 2025-12-04) to 24 (filed 2026-05-14)
- Page number for 'Controls and Procedures' changed from 30 (filed 2025-12-04) to 25 (filed 2026-05-14)
- Page number for 'PART II. OTHER INFORMATION' changed from 32 (filed 2025-12-04) to 26 (filed 2026-05-14)
- Page number for 'Legal Proceedings' changed from 32 (filed 2025-12-04) to 26 (filed 2026-05-14)
- Notes:
- Only table of contents page numbers are present in both excerpts; no substantive MD&A content is provided for comparison
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
5 open-market purchases and 45 open-market sales by insiders in the last 90 days.
- Last 30 days5 buys ($15M) · 1 sell ($276908) — 2 buying, 1 selling insiders
- Last 90 days5 buys ($15M) · 45 sells ($11M) — 2 buying, 6 selling insiders
- Last 180 days5 buys ($15M) · 125 sells ($28M) — 2 buying, 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MPLT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding MPLT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 1,883,348
- Reported value $38,288,465
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MPLT had 3,581,497 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MPLT had 8.44% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.65 days to cover at the same settlement.
- Reported short interest (shares) 3,581,497
- Short interest (% of shares outstanding) 8.44%
- Prior settlement (shares) 3,586,196
- Reported change -0.13%
- Days to cover (reported) 1.65
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novartis
- Roche
- Merck
- Pfizer
- AbbVie
- Bristol Myers Squibb
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MPLT vs…
MAPLIGHT THERAPEUTICS INC is found in…
Frequently asked questions
What does MAPLIGHT THERAPEUTICS INC (MPLT) do?
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutic candidates. The company is advancing preclinical studies and clinical trials for product candidates, with an emphasis on identifying patients and expanding the scope of potential indications for its pipeline. MapLight is pursuing regulatory approvals and commercialization strategies for its therapeutic programs.
What sector is MAPLIGHT THERAPEUTICS INC (MPLT) in?
MAPLIGHT THERAPEUTICS INC (MPLT) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceuticals. It trades on NASDAQ.
Who are MAPLIGHT THERAPEUTICS INC's (MPLT) competitors?
Notable peers of MAPLIGHT THERAPEUTICS INC (MPLT) include Novartis, Roche, Merck, Pfizer and AbbVie. This peer set is informational only — not financial advice.
Is MAPLIGHT THERAPEUTICS INC (MPLT) overbought or oversold right now?
MAPLIGHT THERAPEUTICS INC (MPLT) is currently in oversold territory (its 14-day RSI is 30, below 30) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MPLT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.